ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma withTherapeutic advances in medical oncology · 2026Article
- A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors.Human vaccines & immunotherapeutics · 2024Article
- Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology.Journal of advanced research · 2024Article
- Mapping cancer biology in space: applications and perspectives on spatial omics for oncology.Molecular cancer · 2024Review
- Review
- PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.Cancer immunology, immunotherapy : CII · 2021Article
- The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions.RSC chemical biology · 2021Article
- A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids.Frontiers in oncology · 2021Review
- Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.Cancer biology & medicine · 2020Review
- JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.The Journal of molecular diagnostics : JMD · 2019Article
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.Nature medicine · 2019Article
- Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.Breast cancer research : BCR · 2018Article
- Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Expert opinion on investigational drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amplification of chromosome 9p24.1 encoding PD-L1, PD-L2, and JAK2 has been reported in multiple types of cancer and is associated with poor outcome, upregulation of PD-L1, and activation of the JAK/STAT pathway. We have developed a novel fluorescence in situ hybridization assay which combines 3 probes mapping to 9p24.1 with a commercial chromosome 9 centromere (CEN9) probe for detection of the JAK2/9p24.1 amplification. JAK2 fluorescence in situ hybridization was compared with array-based comparative genomic hybridization in 34 samples of triple negative breast cancer tumor. By array-based comparative genomic hybridization, 15 had 9p24.1 copy-number gain (log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.